BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid-T™ Immunodiagnostic Program
- Thursday, March 18, 2021, 7:12
- PR Newswire
- Add a comment
VANCOUVER, BC, March 18, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys”), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into an agreement with Bioanalytical…
About the Author
admin has written 21643 stories on this site.